B. Riley Securities Maintains Neutral on Theravance Biopharma, Raises Price Target to $17

Benzinga Newsdesk www.benzinga.com Positive 62.4%

Neg 0% Neu 0% Pos 62.4%

B. Riley Securities analyst Mayank Mamtani maintains Theravance Biopharma (NASDAQ:TBPH) with a Neutral and raises the price target from $14 to $17.